In a phase 2 trial, OCU410, a modifier gene therapy for geographic atrophy secondary to dry age-related macular degeneration, ...
OCGN's gene-agnostic eye therapy aims to treat multiple retinal mutations, with key filings and pivotal data in 2026???2027 set to test its broad platform.
Steven Pittler, Ph.D., at the University of Alabama at Birmingham has sought to find modifier genes for the hereditary eye disorder retinitis pigmentosa type 59. After onset in one’s late teens, RP59 ...
The biotech aims to quickly bring three gene therapies to market, and overcome the development and commercialization ...
Add Yahoo as a preferred source to see more of our stories on Google. A genetic eye disorder Ocugen has dosed the first subject in its Phase II/III GARDian3 trial of modifier gene therapy candidate, ...
Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (p< ...
Zacks Investment Research on MSN
Ocugen falls as gene therapy for eye disease lags in phase II study
Shares of Ocugen OCGN declined 8.6% on Tuesday after the company announced 12-month data from the phase II ArMaDa study evaluating its novel modifier gene therapy, OCU410, for treating geographic ...
Ocugen OCGN is pushing three retinal gene therapy programs toward late-stage milestones, with multiple data readouts and ...
CHICAGO (Reuters) - Scientists have discovered a genetic mutation linked with colon cancer that may work like a spigot, controlling the number of precancerous growths that develop and determining a ...
BIRMINGHAM, Ala. – Modifier genes add complexity to precision medicine. A modifier gene is one that has genetic variants such as single nucleotide changes that differ from the most common sequence in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results